Vaccines Market

7500+ companies worldwide approach us every year for their revenue growth inititatives

Global top 2000 strategist rely on us for their growth strategies.

80% of fortune 2000 companies rely on our research to identify new revenue sources.

30000 High Growth Opportunities

95% renewal rate

KNOW MORE

Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024

FREE BROCHURE FREE SAMPLE REPORT

Report Code: PH 6528 Jan, 2020, by marketsandmarkets.com

[188 Pages Report] The global vaccines market is projected to reach USD 58.4 billion by 2024 from USD 41.7 billion in 2019, at a CAGR of 7.0% during the forecast period. The growth of this market is majorly attributed to the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government support for vaccine development, and the rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.

Vaccines Market

Pediatric patients segment accounted for the larger share of the vaccines market, by patient type.

On the basis of patient type, the vaccines market is segmented into pediatric and adult patients. The pediatric patients segment accounted for the largest share of the global vaccines market in 2018. This can be attributed to the increasing government initiatives for immunization and the rising prevalence of diseases.

By technology, the conjugate vaccines segment accounted for the largest market share in 2018.

On the basis of technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. In 2018, the conjugate vaccines segment accounted for the largest share of the vaccines market. The large share of this segment can be attributed to increasing government support and rising company investments in conjugate vaccine development.

Intramuscular & subcutaneous administration segment to witness the highest growth during the forecast period

On the basis of the route of administration, the vaccines market is segmented into intramuscular and subcutaneous administration, oral administration, and other routes of administration. The intramuscular and subcutaneous administration segment accounted for the largest share of the global vaccines market in 2018 and is projected to register the highest CAGR during the forecast period. This mode of administration is associated with better immune response and a lower rate of injection site reactions.

Vaccines Market

North America dominates the vaccines market

North America accounted for the largest share of the vaccines market in 2018. The large share of North America in the global vaccines market is attributed to the high prevalence of infectious diseases and increasing investments by government and non-government organizations for vaccine development. The market in Asia, on the other hand, is projected to register the highest growth during the forecast period. Factors such as the increasing healthcare expenditure and increasing disposable income, government initiatives, and the presence of a large patient population are driving the growth of the vaccines market in Asia.

Key Market Players

The major players in the global vaccines market are GlaxoSmithKline plc. (UK), Pfizer, Inc. (US), Merck & Co., Inc. (US), and Sanofi Pasteur SA (France). Other prominent players in this market include CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), Serum Institute of India (India), AstraZeneca (UK), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan).

Get online access to the report on the World's First Market Intelligence Cloud
Easy to Download Historical Data & Forecast Numbers
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Request Sample
Click on image to enlarge

Scope of the Report

Report Metric	Details
Market size available for years	2017�2024
Base year considered	2018
Forecast period	2019�2024
Forecast units	Value (USD)
Segments covered	Technology, type, disease indication, route of administration, patient type, and region
Geographies covered	North America, Europe, Asia, and the Rest of the World
Companies covered	GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Sanofi Pasteur (France), Merck & Co., Inc. (US), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E (India), Bharat Biotech (India), Sinovac Biotech Ltd. (China), Incepta Vaccine Ltd. (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), and PT Bio Farma (Brazil).

The research report categorizes the vaccines market into the following segments and subsegments:

Technology
- Conjugate vaccines
- Inactivated and subunit vaccines
- Live attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
Type
- Monovalent vaccines
- Multivalent vaccines
Disease Indication
- Pneumococcal disease
- DTP
- Influenza
- HPV
- Meningococcal disease
- Polio
- Rotavirus
- Hepatitis
- MMR
- Varicella
- Herpes zoster
- Other disease indications
Route of Administration
- Intramuscular and subcutaneous administration
- Oral administration
- Other routes of administration
Patient Type
- Pediatric patients
- Adult patients
Region
- North America
- Europe
- Asia
- Rest of the World

Critical questions answered in the report:

How will the current technological trends affect the vaccines market in the long term?
What are the reasons contributing to the growth of the conjugate vaccines segment in the market?
Which regions are likely to grow at the highest CAGR?
What are the challenges hindering the adoption of vaccines?
What are the growth strategies being implemented by major market players?

Frequently Asked Questions (FAQ):

What can be the regulatory challenges expected to be faced by the players in the vaccines market?

The vaccine development and manufacturing process is controlled by regulatory authorities. Licensure for marketing is granted based on three successive phases of clinical development as approved by a national regulatory authority. When a Phase III trial has been completed, the manufacturer must apply for a license to sell the vaccine. The license application review is thorough and takes between one and two years to complete. The regulatory body has the authority to refuse or withdraw a product license if the manufacturer does not comply with current regulations.

Which disease indication segment of vaccines market is expected to witness the highest growth?

Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, and other disease indications. The pneumococcal disease segment accounted for a share of the vaccines market in 2018; this segment is also projected to register a CAGR of during the forecast period. This can be attributed to the high incidence of pneumococcal disease and increasing government investments in pneumococcal vaccination programs.

Which vaccines technology is expected to have highest growth rate in the market for the next 4-5 years?

Based on technology, the vaccines market has been segmented into conjugate vaccines, inactivated & subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. Conjugate vaccines accounted for the largest share of the vaccines market in 2018. This segment is also expected to register highest CAGR of during the forecast period. The large share of this segment can be attributed to the increasing government support and rising company investments in conjugate vaccine development.

Who are the key players operating in the vaccines market?

The global vaccines market is highly competitive, owing to the presence of several large and small players. GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Sanofi Pasteur (France), and Merck & Co., Inc. (US) are the leading players in the global vaccines market. Other notable players in the market are CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca (UK), Serum Institute ofIndia Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), DaiichiSankyo (Japan), Panacea Biotec (India), Biological E (India), Bharat Biotech (India), Sinovac Biotech Ltd. (China), Incepta Vaccine LTD. (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), and Bio Farma(Brazil).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 18)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Market Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 22)
    2.1 Research Approach
           2.1.1 Secondary Research
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Research
                    2.1.2.1 Key Data From Primary Sources
                    2.1.2.2 Breakdown of Primaries
    2.2 Market Size Estimation
    2.3 Data Triangulation Approach
    2.4 Market Share Analysis
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 28)

4 Premium Insights (Page No. - 32)
    4.1 Vaccines Market Overview
    4.2 North America: Vaccines Market, By Technology (2018)
    4.3 Geographical Snapshot of the Vaccines Market

5 Market Overview (Page No. - 35)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 High Prevalence of Infectious Diseases
                    5.2.1.2 Rising Focus on Immunization Programs
                    5.2.1.3 Growing Government Support for Vaccine Development
                    5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D
           5.2.2 Restraints
                    5.2.2.1 High Cost of Vaccine Development
           5.2.3 Opportunities
                    5.2.3.1 High Growth Prospects in Emerging Markets
                    5.2.3.2 Focus on Therapeutic Vaccines
                    5.2.3.3 Use of Adjuvants in Vaccines
           5.2.4 Challenges
                    5.2.4.1 Inadequate Access to Vaccines
           5.2.5 Burning Issues
                    5.2.5.1 Product Recalls

6 Industry Insights (Page No. - 42)
    6.1 Regulatory Landscape
           6.1.1 North America
           6.1.2 Europe
           6.1.3 Asia
           6.1.4 RoW
    6.2 Key Pipeline Products
    6.3 New Vaccine Opportunities
           6.3.1 HIV
                    6.3.1.1 HIV Vaccine: Product Pipeline
                    6.3.1.2 HIV Vaccine: Public-Private Initiatives
                    6.3.1.3 HIV Vaccine: Funding
           6.3.2 Malaria
                    6.3.2.1 Malaria Vaccine: Product Pipeline
                    6.3.2.2 Malaria Vaccine: Public-Private Initiatives
           6.3.3 Zika
                    6.3.3.1 Zika Vaccine: Product Pipeline
                    6.3.3.2 Zika Vaccine: Public-Private Initiatives
                    6.3.3.3 Zika Vaccine: Funding
           6.3.4 Ebola
                    6.3.4.1 Ebola Vaccine: Product Pipeline
                    6.3.4.2 Ebola Vaccine: Public-Private Initiatives
                    6.3.4.3 Ebola Vaccine: Funding
                    6.3.4.4 Ebola projects funded by EC (2014�2020)

7 Vaccines Market, By Technology (Page No. - 56)
    7.1 Introduction
    7.2 Conjugate Vaccines
           7.2.1 Conjugate Vaccines Hold the Largest Share of the Market
    7.3 Inactivated & Subunit Vaccines
           7.3.1 Ease of Storage and Transportation have Made Inactivated & Subunit Vaccines Popular
    7.4 Live Attenuated Vaccines
           7.4.1 Issues in Preserving and Maintaining Live Attenuated Vaccines has Slowed Market Growth
    7.5 Recombinant Vaccines
           7.5.1 Lack of Post-Vaccination Reactions and Reduced Need for Booster Doses are Driving R&D Into Recombinant Vaccines
    7.6 Toxoid Vaccines
           7.6.1 Company Initiatives and the Introduction of New Vaccines Will Support Market Growth

8 Vaccines Market, By Type (Page No. - 64)
    8.1 Introduction
    8.2 Monovalent Vaccines
           8.2.1 in 2018, the Monovalent Vaccines Segment Accounted for the Largest Share of the Market
    8.3 Multivalent Vaccines
           8.3.1 Increasing Initiatives By Companies to Develop New Multivalent Vaccines is Driving the Growth of This Segment

9 Vaccines Market, By Disease Indication (Page No. - 68)
    9.1 Introduction
    9.2 Pneumococcal Disease
           9.2.1 Pneumococcal Disease Segment Accounted for the Largest Share of the Market
    9.3 DTP
           9.3.1 Increasing Accessibility of DTP Vaccines in Developing Countries to Drive Market Growth
    9.4 Influenza
           9.4.1 Influenza Vaccines Segment to Grow at the Highest Rate During the Forecast Period
    9.5 HPV
           9.5.1 Growing Prevalence of HPV Infections to Support Market Growth
    9.6 Meningococcal Disease
           9.6.1 Rising Incidence of Meningococcal Disease to Support the Growth of This Market Segment
    9.7 Polio
           9.7.1 Government Initiatives to Support the Growth of This Market Segment
    9.8 Hepatitis
           9.8.1 High Prevalence of Hepatitis Infections is Driving the Demand for Immunization
    9.9 Rotavirus
           9.9.1 Rising Incidence of Rotavirus Infections to Drive Market Growth
    9.10 MMR
           9.10.1 Rising Incidence of Measles, Mumps, and Rubella Will Support the Growth of This Market Segment
    9.11 Varicella
           9.11.1 Promotion of Immunization Programs to Drive the Demand for Varicella Vaccines
    9.12 Herpes Zoster
           9.12.1 Herpes Zoster Vaccines to Witness Stable Demand During the Forecast Period
    9.13 Other Disease Indications

10 Vaccines Market, By Route of Administration   (Page No. - 85)
     10.1 Introduction
     10.2 Intramuscular and Subcutaneous Administration
             10.2.1 Intramuscular and Subcutaneous Administration Accounted for the Largest Share of the Market
     10.3 Oral Administration
             10.3.1 Possibility of Irritation of the Gastric Mucosa May Limit the Growth of This Segment
     10.4 Other Routes of Administration

11 Vaccines Market, By Patient Type (Page No. - 90)
     11.1 Introduction
     11.2 Pediatric Patients
             11.2.1 In 2018, the Pediatric Patients Segment Accounted for the Largest Share of the Market
     11.3 Adult Patients
             11.3.1 The Adult Patients Segment is Expected to Grow at the Highest CAGR During the Forecast Period

12 Vaccines Market, By Region (Page No. - 94)
     12.1 Introduction
     12.2 North America
             12.2.1 US
                        12.2.1.1 The US is the Largest Market for Vaccines
             12.2.2 Canada
                        12.2.2.1 High Incidence of Infectious Diseases is Driving the Demand for Vaccines in the Country
     12.3 Europe
             12.3.1 Germany
                        12.3.1.1 Significant Investments in R&D to Support Market Growth
             12.3.2 UK
                        12.3.2.1 Launch of New Products to Support Market Growth in the UK in the Coming Years
             12.3.3 France
                        12.3.3.1 Favorable Government Initiatives for Immunization to Support Market Growth in France
             12.3.4 Italy
                        12.3.4.1 Conjugate Vaccines to Account for the Largest Share of the Italian Market
             12.3.5 Spain
                        12.3.5.1 Rising Investments in Vaccine Development By Private Organizations to Support Market Growth in Spain
             12.3.6 Rest of Europe
     12.4 Asia
             12.4.1 Japan
                        12.4.1.1 Government Initiatives for Increasing the Accessibility of Vaccines to Drive Market Growth in Japan
             12.4.2 China
                        12.4.2.1 Growing Investments in the Biotechnology Sector to Drive Market Growth in China
             12.4.3 India
                        12.4.3.1 Growth of the Biotechnology Sector and Development of New Vaccines to Support Market Growth in India
             12.4.4 Rest of Asia
     12.5 Rest of the World
             12.5.1 Latin America
             12.5.2 Other RoW Countries

13 Competitive Landscape (Page No. - 125)
     13.1 Overview
     13.2 Market Share Analysis
     13.3 Competitive Leadership Mapping (Overall Market)
             13.3.1 Visionary Leaders
             13.3.2 Innovators
             13.3.3 Dynamic Differentiators
             13.3.4 Emerging Companies
     13.4 Competitive Situation and Trends
             13.4.1 Agreements, Contracts, and Collaborations
             13.4.2 Product Launches and Approvals
             13.4.3 Acquisitions
             13.4.4 Expansions

14 Company Profiles (Page No. - 132)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
     14.1 Glaxosmithkline PLC
     14.2 Pfizer, Inc
     14.3 Merck & Co., Inc
     14.4 Sanofi Pasteur SA
     14.5 CSL Limited
     14.6 Emergent Biosolutions, Inc
     14.7 Johnson & Johnson
     14.8 Astrazeneca
     14.9 Serum Institute of India Pvt., LTD
     14.10 Bavarian Nordic
     14.11 Mitsubishi Tanabe Pharma Corporation
     14.12 Daiichi Sankyo Company, Limited
     14.13 Panacea Biotec, LTD
     14.14 Biological E
     14.15 Bharat Biotech
     14.16 Other Companies
             14.16.1 Sinovac Biotech, LTD
             14.16.2 Incepta Vaccine, LTD
             14.16.3 Valneva SE
             14.16.4 VBI Vaccines Inc
             14.16.5 PT Bio Farma (Persero)
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

15 Appendix (Page No. - 179)
     15.1 Discussion Guide
     15.2 Knowledge Store: Marketsandmarkets� Subscription Portal
     15.3 Available Customizations
     15.4 Related Reports
     15.5 Author Details

List of Tables (107 Tables)

Table 1 Incidence of Infectious Diseases
Table 2 NIH Funding for Vaccine Research, 2013�2018 (USD Million)
Table 3 Immunization Coverage, By Disease, 2016 vs 2018
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 8 Cost of Meningococcal Conjugate Vaccines for Pediatric Patients
Table 9 Cost of Meningococcal Conjugate Vaccines for Adult Patients
Table 10 Conjugate Vaccines Market, By Region, 2017�2024 (USD Million)
Table 11 Examples of Inactivated & Subunit Vaccines
Table 12 Inactivated & Subunit Vaccines Market, By Region, 2017�2024 (USD Million)
Table 13 Live Attenuated Vaccines Market, By Region, 2017�2024 (USD Million)
Table 14 Examples of Recombinant Vaccines
Table 15 Recombinant Vaccines Market, By Region, 2017�2024 (USD Million)
Table 16 Toxoid Vaccines Market, By Region, 2017�2024 (USD Million)
Table 17 Vaccines Market, By Type, 2017�2024 (USD Million)
Table 18 Monovalent Vaccines Market, By Region, 2017�2024 (USD Million)
Table 19 Examples of Notable Multivalent Vaccines Available in the Market
Table 20 Multivalent Vaccines Market, By Region, 2017�2024 (USD Million)
Table 21 Vaccines Market, By Disease Indication, 2017�2024 (USD Million)
Table 22 List of Commercially Available Pneumococcal Vaccines in the Market
Table 23 Vaccines Market for Pneumococcal Disease, By Region, 2017�2024 (USD Million)
Table 24 List of Commercially Available DTP Vaccines in the Market
Table 25 Vaccines Market for DTP, By Region, 2017�2024 (USD Million)
Table 26 List of Commercially Available Influenza Vaccines in the Market
Table 27 Vaccines Market for Influenza, By Region, 2017�2024 (USD Million)
Table 28 List of Commercially Available HPV Vaccines in the Market
Table 29 Vaccines Market for HPV, By Region, 2017�2024 (USD Million)
Table 30 List of Commercially Available Meningococcal Disease Vaccines in the Market
Table 31 Vaccines Market for Meningococcal Disease, By Region, 2017�2024 (USD Million)
Table 32 List of Commercially Available Polio Vaccines in the Market
Table 33 Vaccines Market for Polio, By Region, 2017�2024 (USD Million)
Table 34 List of Commercially Available Hepatitis Vaccines in the Market
Table 35 Vaccines Market for Hepatitis, By Region, 2017�2024 (USD Million)
Table 36 List of Commercially Available Rotavirus Vaccines in the Market
Table 37 Vaccines Market for Rotavirus, By Region, 2017�2024 (USD Million)
Table 38 List of Commercially Available MMR Vaccines in the Market
Table 39 Vaccines Market for MMR, By Region, 2017�2024 (USD Million)
Table 40 List of Commercially Available Varicella Vaccines in the Market
Table 41 Vaccines Market for Varicella, By Region, 2017�2024 (USD Million)
Table 42 Vaccines Market for Herpes Zoster, By Region, 2017�2024 (USD Million)
Table 43 List of Commercially Available Vaccines for Other Disease Indications
Table 44 Vaccines Market for Other Disease Indications, By Region, 2017�2024 (USD Million)
Table 45 Vaccines Market, By Route of Administration, 2017�2024 (USD Million)
Table 46 Advantages and Disadvantages of Intramuscular and Subcutaneous Administration
Table 47 Vaccines Market for Intramuscular and Subcutaneous Administration, By Region, 2017�2024 (USD Million)
Table 48 Vaccines Market for Oral Administration, By Region, 2017�2024 (USD Million)
Table 49 Vaccines Market for Other Routes of Administration, By Region, 2017�2024 (USD Million)
Table 50 Vaccines Market, By Patient Type, 2017�2024 (USD Million)
Table 51 Vaccines Market for Pediatric Patients, By Region, 2017�2024 (USD Million)
Table 52 North America: Vaccines Market for Pediatric Patients, By Country, 2017�2024 (USD Million)
Table 53 Vaccines Market for Adult Patients, By Region, 2017�2024 (USD Million)
Table 54 North America: Vaccines Market for Adult Patients, By Country, 2017�2024 (USD Million)
Table 55 Vaccines Market, By Region, 2017�2024 (USD Million)
Table 56 North America: Vaccines Market, By Country, 2017�2024 (USD Million)
Table 57 North America: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 58 North America: Vaccines Market, By Type, 2017�2024 (USD Million)
Table 59 North America: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)
Table 60 North America: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)
Table 61 North America: Vaccines Market, By Patient Type, 2017�2024 (USD Million)
Table 62 Number of New Infectious Disease Cases in the Us, 2017
Table 63 US: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 64 US: Vaccines Market, By Patient Type, 2017�2024 (USD Million)
Table 65 Number of New Infectious Disease Cases in Canada
Table 66 Canada: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 67 Canada: Vaccines Market, By Patient Type, 2017�2024 (USD Million)
Table 68 Europe: Vaccines Market, By Country, 2017�2024 (USD Million)
Table 69 Europe: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 70 Europe: Vaccines Market, By Type, 2017�2024 (USD Million)
Table 71 Europe: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)
Table 72 Europe: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)
Table 73 Europe: Vaccines Market, By Patient Type, 2017�2024 (USD Million)
Table 74 Germany: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 75 UK: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 76 France: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 77 Italy: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 78 Spain: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 79 RoE: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 80 Asia: Health Expenditure Per Capita, By Country, 2000, 2014, and 2016 (USD)
Table 81 Asia: Vaccines Market, By Country, 2017�2024 (USD Million)
Table 82 Asia: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 83 Asia: Vaccines Market, By Type, 2017�2024 (USD Million)
Table 84 Asia: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)
Table 85 Asia: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)
Table 86 Asia: Vaccines Market, By Patient Type, 2017�2024 (USD Million)
Table 87 Disease Incidence in Japan, 2016�2018
Table 88 Japan: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 89 China: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 90 India: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 91 RoA: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 92 RoW: Vaccines Market, By Region, 2017�2024 (USD Million)
Table 93 RoW: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 94 RoW: Vaccines Market, By Type, 2017�2024 (USD Million)
Table 95 RoW: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)
Table 96 RoW: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)
Table 97 RoW: Vaccines Market, By Patient Type, 2017�2024 (USD Million)
Table 98 Latin America: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 99 Latin America: Vaccines Market, By Type, 2017�2024 (USD Million)
Table 100 Latin America: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)
Table 101 Latin America: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)
Table 102 Latin America: Vaccines Market, By Patient Type, 2017�2024 (USD Million)
Table 103 Other RoW Countries: Vaccines Market, By Technology, 2017�2024 (USD Million)
Table 104 Other RoW Countries: Vaccines Market, By Type, 2017�2024 (USD Million)
Table 105 Other RoW Countries: Vaccines Market, By Disease Indication, 2017�2024 (USD Million)
Table 106 Other RoW Countries: Vaccines Market, By Route of Administration, 2017�2024 (USD Million)
Table 107 Other RoW Countries: Vaccines Market, By Patient Type, 2017�2024 (USD Million)

List of Figures (35 Figures)

Figure 1 Vaccines Market Segmentation
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Vaccines Market, By Technology, 2019 vs 2024 (USD Million)
Figure 8 Vaccines Market, By Type, 2019 vs 2024 (USD Million)
Figure 9 Vaccines Market, By Disease Indication, 2019 vs 2024 (USD Million)
Figure 10 Vaccines Market, By Route of Administration, 2019 vs 2024 (USD Million)
Figure 11 Vaccines Market, By Patient Type, 2019 vs 2024 (USD Million)
Figure 12 Geographical Snapshot of the Vaccines Market
Figure 13 High Prevalence of Diseases and Rising Focus on Immunization Programs are Driving Market Growth
Figure 14 Conjugate Vaccines Accounted for the Largest Share of the North American Vaccines Market in 2018
Figure 15 Asia to Witness the Highest Growth in the Vaccines Market From 2019 to 2024
Figure 16 Vaccines Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Regulatory Approval Process for Vaccines
Figure 18 North America Will Continue to Dominate the Vaccines Market in 2024
Figure 19 North America: Vaccines Market Snapshot
Figure 20 Europe: Vaccines Market Snapshot
Figure 21 Asia: Vaccines Market Snapshot
Figure 22 Vaccines Market Share Analysis, By Key Player, 2018 127
Figure 23 Competitive Leadership Mapping: Vaccines Market 130
Figure 24 Glaxosmithkline PLC.: Company Snapshot (2018)
Figure 25 Pfizer, Inc.: Company Snapshot (2018)
Figure 26 Merck & Co., Inc.: Company Snapshot (2018)
Figure 27 Sanofi Pasteur SA: Company Snapshot (2018)
Figure 28 CSL Limited: Company Snapshot (2018)
Figure 29 Emergent Biosolutions, Inc.: Company Snapshot (2018)
Figure 30 Johnson & Johnson: Company Snapshot (2018)
Figure 31 Astrazeneca: Company Snapshot (2018)
Figure 32 Bavarian Nordic: Company Snapshot (2018)
Figure 33 Mitsubishi Tanabe Pharma Corporation: Company Snapshot (2018)
Figure 34 Daiichi Sankyo Company: Company Snapshot (2018)
Figure 35 Panacea Biotec: Company Snapshot (2018)

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the vaccines market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the vaccines market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

A breakdown of the primary respondents is provided below:

Vaccines Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by technology, type, disease indication, route of administration, patient type, and region).

Data Triangulation

After arriving at the market size, the vaccines market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments.

Objectives of the Study

To define, describe, and forecast the global vaccines market by technology, type, disease indication, route of administration, patient type, and region
To provide detailed information about the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the vaccines market in four major regions along with their respective key countries (North America, Europe, Asia, and the Rest of the World)
To profile the key players in the global vaccines market and comprehensively analyze their core competencies and market shares
To track and analyze competitive developments such as product launches, expansions, and R&D activities of the leading players in the vaccines market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs. The following customization options are available for the report:

Geographic Analysis

Further breakdown of the vaccines market into South Korea, New Zealand, and other Southeast Asian countries
Further breakdown of the European vaccines market into Belgium, the Netherlands, and Sweden

COVID-19